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In addition, a portable VAD control unit (TLC-II) has
recently become available for clinical evaluation at our
center but is not included in the present study. The con-
sole version of the Thoratec VAD has been described in
detail by Farrar and Hill.1 The system has been accept-
ed for patients with postcardiotomy cardiogenic
shock,2,3 as well as for bridge-to-transplant proce-
dures,3-5 for durations as long as 515 days.
The aim of our work is to describe our 6-year experi-
ence with the implantation of the Thoratec VAD in 114
patients.
Patients and methods
Since our mechanical circulatory support program was
started in September 1987, 382 patients (302 men and 80
women) ranging in age from 4 and 82 years (mean, 52 ± 14
years) received devices for mechanical circulatory assistance.
Between March 1992 and June 1998, the Thoratec VAD was
implanted in 114 patients (98 men and 16 women) between 11
and 64 years of age (mean, 47.9 ± 14.4 years). Nineteen
patients were older than 60 years. Duration of support was 3
to 184 days (mean, 44.9 ± 41.5 days).
System selection. From March 1992 to March 1993, the
Thoratec VAD was the only device available for bridging
patients to transplantation at our center. Since the Novacor
I n recent years, several devices for mechanical circula-tory support have been developed to a stage at
which they are no longer investigational devices. One
of these systems is the Thoratec ventricular assist
device (Thoratec VAD; Thoratec Laboratories Corp,
Pleasanton, Calif). The system can be used for univen-
tricular and biventricular support. Its main components
are the blood pump (located paracorporeally), cannulas,
and a hospital-based drive console, which is large but
enables the patients to be fully ambulant on the system.
Objective: The Thoratec ventricular assist device (Thoratec Laboratories,
Pleasanton, Calif) is widely accepted for univentricular and biventricu-
lar support in patients with various indications. The aim of this study is
to describe our experience with implantation of the Thoratec ventricu-
lar assist device in more than 100 patients. Methods: From March 1992
to June 1998, 114 patients (98 men and 16 women; mean age, 47.9 years)
received the Thoratec ventricular assist device for a mean duration of
44.9 days. The patients were divided into 3 groups. Group 1 included 84
patients in whom the system was applied as a bridge-to-transplant pro-
cedure. Group 2 included 17 patients with postcardiotomy cardiogenic
shock, and group 3 included 13 patients with cardiogenic shock of other
causes. Results: Sixty-eight percent of patients in group 1 survived to
transplantation with a posttransplant survival of 88%. The only inde-
pendent risk factor affecting survival was age more than 60 years.
Survivals in groups 2 and 3 were 47% and 31%, respectively. Main com-
plications in all groups were bleeding, multiple organ failure, liver fail-
ure, sepsis, and neurologic disorders. Conclusions: The Thoratec ventric-
ular assist device has proved to be a reliable device for bridge to
transplantation and postcardiotomy support. Further studies are re-
quired on patient selection and on patient and device management to
reduce the incidence of complications in these patient populations.
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and HeartMate left ventricular assist device (LVAD) systems
have become additionally available in 1993 and 1994, respec-
tively (Novacor: Baxter Healthcare Corp, Oakland, Calif;
HeartMate: Thermo Cardiosystems Inc, Woburn, Mass), our
system selection criteria have been modified. Patients are
selected for biventricular support with the Thoratec VAD if
one of the following conditions is present: central venous
pressure greater than 20 mm Hg and pulmonary artery pres-
sure–central venous pressure gradient of less than 4 mm Hg,
increased pulmonary vascular resistance (>500 dynes · s–1 ·
cm–5), multiple organ dysfunction, or severe malignant
arrhythmias refractory to medical therapy. The other patients
receive a Thoratec LVAD or an implantable LVAD (Novacor
or HeartMate provided the body surface area exceeds 1.5 m2).
Patients. The patients were divided into 3 groups as to
indication of implantation.
Group 1 included 84 patients (72 men and 12 women; age
range, 11-64 years; mean age, 46 ± 15 years) in whom the
system was applied as a bridge-to-transplant procedure after
having received maximum inotropic support and who were at
imminent risk of death. Nineteen (23%) of these patients
were more than 60 years old. Seventeen (20%) patients had
been supported with an intra-aortic balloon pump, 13 (16%)
patients had undergone previous cardiac surgery, 13 (16%)
patients had acute renal failure (requiring renal replacement
therapy preoperatively), and 8 (10%) patients had cardiopul-
monary resuscitation. Forty (48%) patients had liver insuffi-
ciency (defined as bilirubin level >2 mg/dL, aspartate amino-
transferase/alanine aminotransferase level of 3× normal
value, γ-glutamyltransferase of 3× normal value, or alkaline
phosphatase level of 1.5× normal value) before implantation
of the device, and 15 (18%) patients had received artificial
ventilation. Statistical analyses of preoperative risk factors for
death on support (Table I) were performed by using Cox
regression analysis. Patients were censored at the time of
device explant because of weaning or transplantation.
Duration of support in this group was 6 to 184 days with a
mean duration of 50 ± 44 days. The underlying diagnoses
were dilated cardiomyopathy in 53 patients, ischemic car-
diomyopathy in 23 patients, end-stage valvular heart disease
in 4 patients, and miscellaneous other diagnoses in 4 patients.
In 74 patients the Thoratec VAD was applied exclusively. Six
additional patients had first received the centrifugal pump as
femoro-femoral cardiopulmonary bypass, which was then
replaced by Thoratec support, and 4 patients received the
Thoratec device for right ventricular support in addition to
the Novacor LVAS (n = 3) or the electrically driven TCI
HeartMate device (n = 1). Forty-three patients received
biventricular assistance, 34 patients received left ventricular
assistance, 4 patients received Thoratec right ventricular
assistance in combination with a LVAD, and 3 patients
received Thoratec biventricular assist devices (BVADs)
applied as a total artificial heart. For this purpose, the native
heart was excised at atrioventricular level with the tricuspid
and mitral valves left in place. Two straight long ventricular
inflow cannulas were introduced into the right and left atria,
respectively, and fixed with felt. The outflow cannulas were
anastomosed to the aorta and pulmonary artery, respectively,
in an end-to-end fashion. Five of the 84 patients had an aor-
tic valve prosthesis, which was replaced by a bioprosthesis (n
= 2) or by the Thoratec VAD used as a total artificial heart (n
= 3).
Group 2 comprised 17 patients (15 men and 2 women; age
range, 42-63 years; mean age, 54 ± 6 years) who had post-
cardiotomy cardiogenic shock after coronary artery bypass
grafting (CABG, n = 13), aortic valve replacement (n = 2),
tricuspid valve replacement (n = 1), and concomitant mitral
valve replacement and CABG (n = 1). Nine patients received
the device in the operation after unsuccessful weaning from
extracorporeal circulation, and 8 patients had cardiogenic
Table I. Outcome of patients bridged to transplanta-
tion with regard to preoperative risk factors for death
P value 
Risk factor for death Transplanted (Cox regression)
IABP (n = 17) 9 (53%) .9
Reoperation (n = 13) 8 (62%) .8
Acute renal failure (n = 13) 10 (77%) .5
CPR (n = 8) 4 (50%) .3
Age over 60 y (n = 19) 9 (47%) .05
Liver insufficiency (n = 40) 28 (70%) .3
BVAD (n = 43) 28 (65%) .7
Previous VAD (n = 6) 2 (33%) .3
Ventilation (n = 15) 7 (47%) .14
IABP, Intra-aortic balloon pumping; CPR, cardiopulmonary resuscitation.
Table II. Patient age and preoperative variables
(mean values)
LVAD BVAD 
(n = 50) (n = 55) P value
Age (y) 49.9 ± 12.0 46.2 ± 16.0 .17
Hemodynamics
CI (L · min–1 · m–2) 1.9 ± 0.7 2.2 ± 0.2 .53
CVP (mm Hg) 13.5 ± 4.5 17.6 ± 4.0 .007
PAP (mm Hg) 33.3 ± 9.0 35.0 ± 7.0 .54
PVR 260 ± 135 349 ± 189 .29
(dynes · s–1 · cm–5)
SVR 1510 ± 891 913 ± 252 .06
(dynes ·s–1 · cm–5)
Laboratory variables
AP (U/L) 133.9 ± 64.0 174.6 ± 85.0 .082
BUN (mg/dL) 80.2 ± 39.3 113.4 ± 67.9 .025
Bilirubin (mg/dL) 1.8 ± 0.9 3.0 ± 2.9 .024
Creatinine (mg/dL) 1.8 ± 0.9 2.1 ± 1.3 .377
γ-GT (mg/dL) 53.9 ± 44.1 61.0 ± 42.3 .583
AST (U/L) 126.2 ± 213.4 119.6 ± 262.1 .919
ALT (U/L) 143.7 ± 180.6 115.2 ± 218.9 .607
CI, Cardiac index; CVP, central venous pressure; PAP, pulmonary artery pres-
sure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance;
AP, alkaline phosphatase; BUN, blood urea nitrogen; GT, glutamyltransferase;
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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shock postoperatively in the intensive care unit. In contrast to
group 1, these patients were not listed for cardiac transplan-
tation at the time of device implantation. Duration of support
was 3 to 117 days (mean, 32 ± 30 days). Eleven patients
received exclusive Thoratec support, 4 patients were first sup-
ported with the centrifugal pump (in 1 patient as femoro-
femoral cardiopulmonary bypass and in 3 patients as LVAD),
and 2 were initially supported with the Abiomed biventricu-
lar system (Abiomed, Inc, Danvers, Mass), which was later
replaced by a Thoratec BVAD. Six patients required biven-
tricular assistance, and 11 patients left ventricular assistance.
The 13 patients of group 3 (11 men and 2 women; age
range, 15-63 years; mean age, 49 ± 14 years) received the
Thoratec device for cardiogenic shock of different causes,
such as acute myocardial infarction (n = 5), fulminant
myocarditis (n = 2), primary graft failure (n = 1), and acute
rejection (n = 5). At the time of implantation, these patients
were not candidates for a transplant procedure. Duration of
support in this group was 6 to 111 days, with a mean duration
of 26 ± 28 days. Exclusive assistance with a Thoratec device
was applied in 8 patients, and 5 patients had first received a
centrifugal pump as a femoro-femoral cardiopulmonary
bypass. Six patients required biventricular support, 5 patients
required left ventricular support, and 2 patients had Thoratec
BVADs applied as total artificial heart.
Values for preoperative variables in patients with left and
biventricular assistance are summarized in Table II.
Cannulation approach and implantation criteria. In
patients undergoing bridge-to-cardiac transplantation, ven-
tricular cannulation is our method of choice because it pro-
vides higher VAD flow rate and better washing of the native
left ventricle. In patients with postcardiotomy cardiogenic
shock, atrial cannulation is preferred if a recovery of the ven-
tricle can be expected. Our criteria for implantation have been
published elsewhere.2,3
Anticoagulation protocol. In the first 24 hours postopera-
tively, the patients receive no anticoagulation. Thereafter,
therapy is started with heparin according to the activated clot-
ting time (1.5× initial value). After removal of chest drains,
phenprocoumon (Narcumar) administration is started (dosage
according to the international normalized ratio, 2.5-3.5).
Aprotinin was administered preoperatively in patients under-
going reoperation and postoperatively in all patients with a
bleeding complication.
Antibiotic protocol. Our antibiotic and infection manage-
ment protocol consists of a short-term prophylactic adminis-
tration of cefazolin (3× 2 g daily) in all patients until all
drainages are removed. Percutaneous cannula exit sites are
cleaned and prepared every 3 days with 2% merbromin.
Patients with local exit site infections only do not receive spe-
cific systemic treatment. If systemic signs of infection devel-
op, they are given antibiotics according to the antimicrobial
sensitivity test (usually Staphylococcus aureus) starting with
floxacillin (INN: flucloxacillin), 6 to 8 g daily. If methicillin-
resistant Staphylococcus aureus is present, therapy is started
with vancomycin, with the dosage depending on blood level
Table III. Outcome
Bridging Postcardiotomy heart failure Miscellaneous Total 
Outcome (n = 84) (n = 17) (n = 13) (n = 114)
Weaned 2 1 — 3
Transplanted 57 (68%) 7 (41%) 4 (31%) 68 (60%)
Discharged 50 (60%) 8 (47%) 4 (31%) 62 (54%)
Death on support 25 (30%) 9 (53%) 9 (69%) 43 (38%)
Table IV. Complications
Complication BTT (n = 84) PC (n = 17) Miscellaneous (n = 13)
Bleeding 26 (31%) 2 (12%) 2 (15%)
Multiple organ failure 20 (24%) 5 (29%) 4 (31%)
Sepsis 13 (16%) 6 (35%) 5 (39%)
Liver failure 18 (21%) 2 (12%) 1 (8%)
Neurologic 16 (19%) 3 (18%) 1 (8%)
Pneumonia 9 (11%) 2 (12%) 1 (8%)
Gastrointestinal 11 (13%) — —
Exit site infection 11 (13%) — —
Acute renal failure 8 (10%) 2 (12%) —
Right heart failure* 4 (12%) 1 (9%) —
Hemolysis 4 (5%) 2 (12%) 1 (8%)
Technical 3 (4%) 1 (6%) —
Mediastinitis 1 — —
BTT, Bridge to transplant; PC, postcardiotomy cardiogenic shock.
*In patients with Thoratec left ventricular support (bridging, n = 34; postcardiotomy, n = 11).
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(20-40 mg/L). In case the infection cannot be controlled by
this antibiotic regimen, rifampin (INN: rifampicin; 10 mg/kg
body weight daily) according to liver and renal function is
administered additionally. This additional antibiotic regimen
is applied for at least 4 weeks.
Results
In group 1, 57 (68%) patients underwent transplanta-
tion, 50 (60%) of whom could be discharged from the
hospital (Table III). Posttransplant survival through
hospital discharge was 88%. Two patients could be
weaned from right ventricular support with the
Thoratec device and were then successfully bridged to
cardiac transplantation by using Novacor left ventricu-
lar assistance. Of those 3 patients who had received the
device as a total artificial heart, 2 could be discharged
after transplantation, and the third patient died from
multiple organ failure and sepsis under support. Both
patients with a bioprosthesis in the aortic position were
survivors; one had a transient ischemic attack after
implantation. The only independent risk factor for
death on the assist device turned out to be patient age
over 60 years (Table I). Main complications were
bleeding (31%), multiple organ failure (24%), liver
failure (21%), and neurologic disorders (18%), which
occurred from postoperative days 5 to 120 (mean, 37 ±
26 days; Table IV). Six of 11 patients with gastroin-
testinal complications had to undergo surgery under
support, with 5 survivors and 1 death.
In group 2, 1 patient who had undergone CABG could
be weaned and discharged from the hospital. Seven
(41%) patients whose native heart did not recover had
successful transplantation and were discharged (post-
transplant survival rate, 100%). Survival in this group
was 47% (Table III). Five (36%) of 14 patients after
CABG, both of whom had aortic valve replacement, and
the patient with the combined procedure were survivors.
Six (55%) of 11 patients with LVAD and 2 (33%) of 6
patients with BVAD support survived to be discharged.
Most frequent complications were sepsis (35%) and
multiple organ failure (29%, Table IV).
In group 3, only 4 (31%) of the 13 patients (1 with
myocarditis, 1 with rejection, 1 with acute myocardial
infarction, and 1 with primary graft failure) underwent
transplantation and were discharged from the hospital
(posttransplant survival, 100%; Table III). Both
patients with the total artificial heart, 1 (20%) of 5
patients with an LVAD, and 1 (17%) of 6 patients with
a BVAD survived. Main complications were sepsis
(39%) and multiple organ failure (31%, Table IV).
Altogether, 68 (60%) patients underwent heart trans-
plantation, and 6 of them died after the procedure.
Sixty-two (54%) patients could be discharged home.
The posttransplant survival was 91%.
In 5 patients (3 bridge-to-transplant and 2 postcar-
diotomy patients) the sternum could not be completely
closed immediately at the end of surgery but had to be
closed 2 to 5 days postoperatively. Two of these
patients (1 bridge-to-transplant and 1 postcardiotomy
patient) died from multiple organ failure, and the other
3 patients underwent successful transplantation.
Right heart failure developed in 5 patients initially
supported with an LVAD. In two cases, it was refractory
to pharmacologic therapy, which did not include nitric
oxide because it is not available in our operating room.
These two patients received the Thoratec right ventricu-
lar assist device in addition to the primary left ventricu-
lar support. One patient supported as a bridge-to-trans-
plant procedure died OF multiple organ failure, and the
other patient supported for postcardiotomy cardiogenic
shock was discharged after successful transplantation.
The main causes of death in all groups (n = 52) were
multiple organ failure and sepsis.
During our cumulative experience of 13.2 patient-
years, there were no major technical problems (eg, rup-
ture of blood sac and VAD replacement). Minor techni-
cal complications occurred in 4 patients (LVAD
compressor failure and driveline kinking), but these did
not have any negative effect for the patients.
Discussion
This study describes our experience with the
Thoratec VAD in more than 100 patients with different
indications. Generally, our cumulative experience of
13.5 patient-years without major technical problems
has proved the reliability of the system. Another advan-
tage of the device is its versatility because it can be
applied for right, left, and biventricular support with
the possibility of atrial and ventricular cannulation, as
has also been described by other authors.1,4-8 However,
the size of the drive console and the paracorporeal loca-
tion of the blood pumps make the system unsuitable in
some patients for long-term support, although other
centers have had successful experience up to 515 days.
To address these issues, Thoratec has recently intro-
duced a small portable briefcase-size control unit,
which greatly improves patient mobility,6,7,9 and they
are developing an intracorporeal version of their ven-
tricular assist device.
Mechanical circulatory support still is associated
with serious complications in these critically ill patient
populations. Bleeding amounted to 26% in our collec-
tive experience, which is comparable with or lower
than that found in other reports,1,8 although these inves-
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tigations only considered patients bridged to transplan-
tation. Compared with our early experience, the bleed-
ing complication declined as a result of the learning
curve,3,10 principally because of our efforts to maintain
meticulous hemostasis during surgical implantation.
The high prevalence of multiple organ failure, liver
failure, and sepsis resulted from the poor preoperative
condition of the patients who often had multiple organ
dysfunction and, with surgical trauma, frequently have
organ failure.
The prevalence of all forms of neurologic complica-
tions (n = 20, 18%) was high but within the range for
other devices; for example, in the HeartMate Food and
Drug Administration clinical trial, the prevalence of
neurologic dysfunction was 21%.11 Not all of the com-
plications were considered to be related to devices.
Three patients had cerebral bleeding, which occurred
after cerebral infarction in one case, and in the other
two cases probably resulted from anticoagulation. Four
patients had transient ischemic attacks, and in one of
them the attack was associated with an infection com-
plication. Two patients, who had received Thoratec
support during cardiopulmonary resuscitation, had
paraplegia detected shortly after implantation. Eleven
patients had hemiplegia during support 2 to 18 weeks
postoperatively, 7 of whom recovered and underwent
transplantation. In 4 patients, hemiplegia occurred after
an infection. Thus 12 (11%) patients (11 with hemiple-
gia and 1 with cerebral bleeding) had major neurologic
disorders, which could be related to a device, and in the
absence of infection, the prevalence was 7%.
Gastrointestinal complications were upper gastroin-
testinal tract bleeding and cholecystitis in 3 patients
each and mesenteric ischemia in 5 patients. Abdominal
surgery was necessary under support in 6 patients
(cholecystectomy and hemicolectomy in 2 cases each
and appendectomy and splenectomy in 1 case each).
The prevalence of exit site infections was considerably
low because of our strict redressement regimen under
sterile conditions by a trained VAD team. It did not at
all occur in patients with postcardiotomy cardiogenic
shock and with other indications, probably because of
the lower duration of support.
The Thoratec VAD has proved to be a reliable device
for bridge-to-transplant and postcardiotomy support.
The large hospital-based console, however, represented
a disadvantage limiting the mobility of the patient.
Currently, the portable VAD driver has become avail-
able, which is significantly improving the quality of
life of VAD patients.6,7,9 Patient age of more than 60
years turned out to be the only independent risk factor
affecting survival.
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